Sugrue D, McEvoy M, Feely J, Drury M I
Q J Med. 1980 Winter;49(193):51-61.
A review of the outcome of treatment by subtotal thyroidectomy, radio-iodine and carbimazole of 837 patients with hyperthyroidism seen consecutively over the period 1954--78 inclusive is presented. The age and sex distribution, the male to female ratio, the ABO blood group distribution and the prevalence of pernicious anaemia and diabetes mellitus in these patients was also analysed. Life-table data showed that the five-year and ten-year cumulative relapse rates following a two-year course of carbimazole (n = 162) were 56 per cent and 62 per cent; following surgery (n = 266), 6 per cent and 10 per cent and following radio-iodine (n = 43), 3 per cent and 14 per cent. Five-year and ten-year cumulative hypothyroid rates after surgery were 10 per cent and 18 per cent, and after radio-iodine 10 per cent and 30 per cent. Hypothyroidism did not occur after carbimazole therapy. Of 31 patients who took carbimazole for less than two years (mean 11 months, range 6--19 months), 91 per cent had relapsed at five years. Of 79 patients treated for longer than two years (mean 3.8 years, range 2 1/2--14 years), relapse rates at five and eight years were 49 per cent and 62 per cent. Nine patients (3.4 per cent) suffered permanent vocal cord paralysis and five (1.9 per cent) had permanent hypocalcaemia. The male/female ratio was 9.9 to 1, with a peak female prevalence between 25 and 30 years and a peak male prevalence between 40 and 45 years. The ABO blood group distribution among patients did not differ significantly from the distribution in the general population (chi 2 = 13.4, p = 0.2). Forty-seven patients (5.6 per cent) had diabetes mellitus and thyrotoxicosis whilst two patients (0.23 per cent) had diabetes, thyrotoxicosis and pernicious anaemia.
本文回顾了1954年至1978年(含)期间连续诊治的837例甲亢患者接受甲状腺次全切除术、放射性碘和卡比马唑治疗的结果。还分析了这些患者的年龄和性别分布、男女比例、ABO血型分布以及恶性贫血和糖尿病的患病率。生命表数据显示,接受两年卡比马唑疗程(n = 162)后的五年和十年累积复发率分别为56%和62%;手术后(n = 266)分别为6%和10%,放射性碘治疗后(n = 43)分别为3%和14%。手术后五年和十年的累积甲状腺功能减退率分别为10%和18%,放射性碘治疗后分别为10%和30%。卡比马唑治疗后未发生甲状腺功能减退。31例服用卡比马唑少于两年(平均11个月,范围6至19个月)的患者中,91%在五年时复发。79例治疗超过两年(平均3.8年,范围2.5至14年)的患者中,五年和八年的复发率分别为49%和62%。9例患者(3.4%)发生永久性声带麻痹,5例患者(1.9%)发生永久性低钙血症。男女比例为9.9比1,女性患病率高峰在25至30岁之间,男性患病率高峰在40至45岁之间。患者的ABO血型分布与普通人群的分布无显著差异(χ² = 13.4,p = 0.2)。47例患者(5.6%)患有糖尿病和甲状腺毒症,2例患者(0.23%)患有糖尿病、甲状腺毒症和恶性贫血。